Charlène Brochard

Charlène Brochard

Auto-generated profile, based on publicly available information

Charlène Brochard

Department of Physiology Digestive Disease, CHU Rennes and University of Rennes INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer), F-35000 Rennes, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2017 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
FMFrancois MION
Francois MION
AGA. Garros
A. Garros
CBC. Brochard
C. Brochard
VVV. Vitton
V. Vitton
ARA. Ropert
A. Ropert
SRS. Roman
S. Roman

27 December 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CLCamille Lucidarme
Camille Lucidarme
APAntoine Petitcollin
Antoine Petitcollin
CBCharlène Brochard
Charlène Brochard
LSLaurent Siproudhis
Laurent Siproudhis
MDMarie Dewitte
Marie Dewitte
GBGuillaume Bouguen
Guillaume Bouguen
Summary: Background: There are limited data concerning infliximab drug monitoring during de‐escalation of the treatment of inflammatory bowel disease (IBD).Aim: To define the rate and the predictors of relapse following infliximab de‐escalation in IBD patients in remission.Methods: All IBD patients at a single referral centre in clinical and biological remission and in whom the dose of infliximab had been de‐escalated were included. Patients in remission with a high trough level of infliximab (>7 mg/L) were considered to be trough level‐based de‐escalation patients. The data were retrieved from a prospective IBD database. Actuarial analysis was performed for statistical purposes.Results: A total of 146 de‐escalations were performed in 96 patients (Crohn's disease/ulcerative colitis: 68%/32%); 54 (37%) were based on clinical remission only, and 92 (63%) were based on clinical remission associated with a trough level above 7 mg/L. The cumulative probabilities of relapse following infliximab de‐escalation were 16% and 47% at 1 and 2 years, respectively. Ulcerative colitis was associated with an increased risk of relapse (HR = 3.2, P = 0.005). Conversely, combination therapy at infliximab initiation (HR = 0.39, P = 0.0110) and trough level‐based de‐escalation were associated with decreased risk of relapse (HR = 0.45, P = 0.024). Trough levels before and after de‐escalation were well correlated; a decrease by half was observed following a 2‐week interval increase or a half‐dose decrease.Conclusion: The use of trough levels to assess the feasibility of dose de‐escalation seems to be a prerequisite for decreasing the risk of relapse.

1 November 2019 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
CBCharlène Brochard
Charlène Brochard
MCMarion Chambaz
Marion Chambaz
ARAlain Ropert
Alain Ropert
ALAlexandre Merlini L’hÉritier
Alexandre Merlini L’hÉritier
TWTimothée Wallenhorst
Timothée Wallenhorst
LSLaurent Siproudhis
Laurent Siproudhis

1 October 2016 in Digestive and Liver Disease
Verified
Journal Article
Closed access
AMAnne-Laure Mallet
Anne-Laure Mallet
ARAlain Ropert
Alain Ropert
GBGuillaume Bouguen
Guillaume Bouguen
LSLaurent Siproudhis
Laurent Siproudhis
DBDominique Boutroux
Dominique Boutroux
CBCharlène Brochard
Charlène Brochard

1 November 2017 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
CBCharlène Brochard
Charlène Brochard
BPBenoît Peyronnet
Benoît Peyronnet
ADAnne Dariel
Anne Dariel
HMHélène Ménard
Hélène Ménard
AMAndréa Manunta
Andréa Manunta
LSLaurent M.D. Siproudhis
Laurent M.D. Siproudhis
BACKGROUND: Although care of urological disorders in spina bifida is well established, there is yet no agreement on a standardized approach to bowel dysfunction in this population. OBJECTIVE: The purpose of this study was to assess bowel dysfunction using validated instruments and the risk factors in adults with spina bifida. DESIGN: A multidisciplinary team prospectively collected patient data, focusing on anorectal and urological symptoms. SETTINGS: The study was conducted with data from a French referral center for spina bifida. PATIENTS: A total of 228 adults with spina bifida (sex ratio men:women, 92 (40%):136 (60%)) with a median age of 34.7 years (range, 26.8–44.7 y) were assessed. MAIN OUTCOMES MEASURES: Factors associated with severe fecal incontinence (Cleveland Clinic Incontinence Score ≥9) and severe bowel dysfunction (Neurogenic Bowel Dysfunction score ≥14) were assessed in a multivariate analysis model. RESULTS: The prevalence rates of severe fecal incontinence and severe bowel dysfunction were 60% (130/217) and 42% (71/168). Bowel dysfunction was the second most common major concern of patients after lower urinary tract dysfunction. Male sex, obesity, urinary incontinence, and a Knowles–Eccersley–Scott symptom constipation score ≥10 were independently associated with severe fecal incontinence. Patients with soft stools had significantly less severe bowel dysfunction. Neither neurologic level nor other neurologic features of spina bifida were associated with severe fecal incontinence or severe bowel dysfunction. LIMITATIONS: The recruitment of patients with spina bifida through a national referral center might have resulted in selection bias, and some data were missing especially regarding BMI and Neurogenic Bowel Dysfunction score (21% and 26% of missing data). CONCLUSIONS: The prevalence rates of severe fecal incontinence and severe bowel dysfunction in adults with spina bifida were high and were adequately perceived by the patients. The present study emphasized the association of bowel dysfunction and fecal incontinence with obesity, urologic disorders, and stool consistency rather than neurologic features. See Video Abstract at http://links.lww.com/DCR/A394 .

23 February 2017 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
CBC. Brochard
C. Brochard
AVA. Vénara
A. Vénara
ABA. Bodère
A. Bodère
ARA. Ropert
A. Ropert
GBG. Bouguen
G. Bouguen
LSL. Siproudhis
L. Siproudhis